Dispute Resolution: Ardelyx Eyes Tenapanor Resubmission Following Successful Appeal To FDA
Executive Summary
Office of New Drugs grants company’s appeal of complete response letter for tenapanor in dialysis patients, marking a rare sponsor victory through the agency’s formal dispute resolution process; new drug application resubmission is targeted for first half of 2023.
You may also be interested in...
House Lawmakers Could Receive A Mountain Of Docs On US FDA Scientific Disagreements
The request from House Energy and Commerce Committee Republicans states they are worried about retaliation against career agency staff.
Minutes Matter: Why The US FDA Refuses To Record Formal Meetings
Given confusion sometimes emerges about the content of formal meeting minutes, recording the meetings would seem like an easy solution, but also could muddy the administrative record.
Minutes Matter: Why The US FDA Refuses To Record Formal Meetings
Given confusion sometimes emerges about the content of formal meeting minutes, recording the meetings would seem like an easy solution, but also could muddy the administrative record.